期刊
EUROPEAN JOURNAL OF CANCER
卷 39, 期 13, 页码 1899-1903出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0959-8049(03)00376-9
关键词
neuroblastoma; relapse; tumour markers; vanillylmandelic acid; homovanillic acid; neurone-specific enolase; lactate dehydrogenase; follow-up
类别
The value of the tumour markers vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine (u) and serum (s), neurone-specific enolase (NSE). and lactate dehydrogenase (LDH) in the early prediction of relapse/progression in neuroblastoma is not known. We analysed the data of neuroblastoma patients who had successfully completed first-line treatment and had laboratory results available from their initial diagnosis and from relapse/progression (n = 196). Patients' overall survival from relapse or progression was 21.5 +/- 4.2% (mean standard deviation). At diagnosis, we found abnormal results in 75% for VMA and/or HVA (s), 92% for VMA and/or HVA (u), 90% for NSE, and 81% for LDH. We found a lower incidence of abnormal results at relapse or progression,with 40% for VMA and/or HVA (s), 54% for HVA and/or VMA (u), 61% for NSE, and 48% for LDH. Sensitivity of markers was higher for metastatic compared with local recurrence. NSE was the best, being able to detect 42% of the localised relapses. 77% of the combined local/metastatic relapses, and 69% of the metastatic recurrences. Relapse or progression in neuroblastoma cannot be detected reliably by monitoring tumour markers alone. Therefore, follow-up of neuroblastoma patients must include clinical assessment and imaging studies. (C) 2003 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据